The new AAP schedule provides guidance for routine immunization against 18 diseases, including updates for RSV, influenza, and COVID-19 immunization.

For adults, RSV vaccines show continued protection even two years after immunization. Based on this, the CDC recommends only one dose of the RSV vaccine for seniors right now, but this may change ...

RSV vaccines aren't needed every year. Federal regulators recommend a single dose of RSV vaccine, so If you were vaccinated last year, you won't need another dose this year.

Respiratory syncytial virus, or RSV, is a common respiratory virus that spreads seasonally. A new drug and several vaccines that prevent the infection have recently come to market. Here's what you ...

RSV: A vaccine targeting respiratory syncytial virus (RSV) has been approved for adults age 60 and older. Monoclonal antibody products (which are not vaccines) are also available to protect ...

RSV vaccines for babies, older adults and pregnant people are in the works from several companies. Here's the latest data and information.

A vaccine to protect against severe cases of Respiratory Syncytial Virus could roll out as early as August. Pfizer has developed RSVpreF, a vaccine to prevent severe cases of RSV, and the Food and ...

The US Food and Drug Administration has approved a vaccine against the respiratory syncytial virus, or RSV, for adults 60 and older. This vaccine, called Arexvy, is made by the drug company GSK.

The Food and Drug Administration on Wednesday approved Arexvy, the world's first respiratory syncytial virus (RSV) vaccine — a scientific breakthrough 60 years in the making.

A vaccine to protect infants in their first six months of life — the age group at highest risk of being hospitalized with RSV — is expected to gain FDA approval later this year.

A Pfizer vaccine to protect older adults and infants from respiratory syncytial virus (RSV) infection has shown what some scientists are calling “exciting” promise in late-stage trials.